Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03026855|
Recruitment Status : Completed
First Posted : January 20, 2017
Last Update Posted : January 20, 2017
|Condition or disease||Intervention/treatment||Phase|
|Chronic Ulcer||Biological: Autologous PRP Gel and PRP Injection||Phase 1|
Platelet Rich Plasma (PRP) therapy is an innovative treatment that uses body's own cells to relieve pain and promote accelerated healing of Non-healing Foot Ulcer /Wound. The body's response to any tissue injury is to deliver platelets, which play an instrumental role in the normal healing process by secreting growth factors and attracting stem cells—critical components of the healing cascade.
Any wound or ulcer on skin that has been present for 4-5 weeks duration, without healing is called a non-healing ulcer. Non-healing ulcers include venous, arterial, diabetic, pressure and traumatic ulcers. Cellular therapies using Autologous Platelet Rich Plasma provides new options for wound healing. The efficacy of the treatment has been proven in surgical applications, in the treatment of severe burns and in transplantation of cells and tissues.
Local application of a solution of plasma enriched in platelets derived from the patient's blood intends to trigger the healing process in non-responsive chronic wound, increase the wound repair rate and reduce pain. PRP is a good option for non-healing wounds because it utilizes the body's natural healing processes to jump-start wound healing. Plasma which contains very valuable growth factors is separated from other blood components utilizing a point of care technology based on density gradient centrifugation. The platelet rich plasma is harvested and then activated by a mixture of human thrombin and calcium chloride for initiating the healing cascade followed by PRP injection directly into the ulcer/wound periphery or spread over a wound in the form of a PRP gel.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||To Demonstrate the Safety and Efficacy of Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers|
|Study Start Date :||June 2014|
|Primary Completion Date :||April 2016|
|Study Completion Date :||May 2016|
Experimental: Autologous PRP Gel and PRP Injection
Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
Biological: Autologous PRP Gel and PRP Injection
Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.
Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.
Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment.
- Number of Wound/ Ulcers Healed [ Time Frame: 24 weeks ]The number of wound/ ulcers healed will be assessed by visual inspection of reduction in wound size at 24 weeks post PRP therapy
- Time to Ulcer Healing [ Time Frame: 24 weeks ]The average time taken for the ulcers to heal post PRP administration
- Reduction in Pain using VAS pain score [ Time Frame: 24 weeks ]Improvement in Pain and discomfort following PRP therapy
- Changes in Quality of Life using the SF-36 Questionnaire [ Time Frame: 24 weeks ]Improvement in Quality of Life of the patients following PRP therapy
- Number of participants with treatment-related Adverse Events [ Time Frame: 24 weeks ]Safety of the treatment will be assessed by measuring the number of treatment related adverse events and adverse reactions during the follow-up period
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03026855
|Fortis Escorts Heart Institute and Research Centre|
|Delhi, India, 110025|
|Principal Investigator:||Dr. Suhail N Bukhari, MBBS, DNB||Fortis Escorts Heart Institute and Research Centre|